Approved: Dissecting the Teva-Allergan merger

The Federal Trade Commission was quick to highlight that it had required global pharmaceutical giant Teva to unload 79 generic drugs — the largest drug divestiture in one of its cases — before allowing the company to consummate its $40.5 billion deal for Allergan’s generic business.

The commission also examined